AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Spyre Therapeutics Inc. (SYRE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

22.22

-0.15 (-0.67%)

At close: Feb 20, 2025, 3:59 PM

22.41

0.86%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	21.3
Market Cap	1.30B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-37.9
PE Ratio (ttm)	-0.59
Forward PE	n/a
Analyst	Buy

Ask	23.34
Volume	227,079
Avg. Volume (20D)	558,952
Open	22.18
Previous Close	22.37
Day's Range	21.63 - 23.04
52-Week Range	20.07 - 47.97
Beta	undefined

About SYRE

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates desig...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 7, 2016

Employees 60

Stock Exchange NASDAQ

Ticker Symbol SYRE

Website https://www.spyre.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for SYRE stock is "Buy." The 12-month stock price forecast is $49.5, which is an increase of 122.77% from the latest price.

Buy 87.50%

Hold 12.50%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Spyre Therapeutics Inc. is scheduled to release its earnings on Mar 3, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-8.97%

Spyre Therapeutics shares are trading lower. The c... Unlock content with Pro Subscription

11 months ago

-11.68%

Spyre Therapeutics shares are trading lower after the company announced a $180 million private placement of its Series B non-voting convertible preferred stocks at a price of $1,480 per share.

News

1 week ago · zacks.com

Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 158.9% upside potential for Spyre Therapeutics (SYRE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

2 weeks ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors ar...

2 weeks ago · accessnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors ar...

4 weeks ago · accessnewswire.com

ATTENTION SYRE SHAREHOLDERS: Investors who Lost Money on Spyre Therapeutics, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spyre Therapeutics, Inc. ("Spyre Therapeutics, Inc.") (NASDAQ:SYR...

4 weeks ago · accessnewswire.com

Lost Money on Spyre Therapeutics, Inc. (SYRE)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK CITY, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Spyre Therapeutics, Inc. ("Spyre Therapeutics, Inc.") (NASDAQ:SYR...

2 months ago · https://thefly.com

TD says Spyre has 'superior TL1A program' after Teva data

TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to i...

2 months ago · https://thefly.com

Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG

BTIG analyst Julian Harrison notes that Teva's (TEVA) enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A asset that "they only own 50% rights to" plus $1B in dev...